Development of clinical recommendations “Cystitis in women”


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article is devoted to the stages of developing clinical recommendations on bacterial cystitis in accordance with the order of the Ministry of Health of Russia. Principles of evidence - based medicine (meta-analyses, systematic reviews and randomized clinical trials) are given. The Evidence Validity Level Assessment Scale (TDS) and Recommendation Credibility Level Assessment Scale (TDS) are given. In accordance with these requirements, modern methods for diagnosing bacterial cystitis have been selected, including the Acute Cystitis Symptom Score (ACSS), and the urination diary. Current approaches to treatment of asymptomatic bacteriuria, antimicrobial treatment regimens of acute and recurrent bacterial cystitis are given. Evidence-based methods of cystitis recurrence prevention are presented. Information is also provided for patients, including lifestyle recommendations, water regime, risk factors for cystitis recurrences, and explanations for completing questionnaires and diaries.

Full Text

Restricted Access

About the authors

T. S Perepanova

N.A. Lopatkin Research Institute of Urology and Interventional Radiology - a branch of the National Medical Research Radiological Center; Russian Society of Urologists

Email: perepanova2003@mail.ru
MD, professor, Head of Infectious and Inflammatory Diseases and Clinical Pharmacology Panel of the Department of General and Reconstructive Urology Moscow, Russia; Moscow, Russia

References

  1. Kunin C.M. Urinary Tract Infections: Detection, Prevention and Management. 5th ed. - Baltimore: Williams & Wilkins, 1997.
  2. Hooton T.M. Uncomplicated urinary tract infections. New England Journal of Medicine.2012; 366:1028-37;
  3. Перепанова Т.С. Неосложненная инфекция мочевых путей. В кн: «Рациональная фармакотерапия в урологии: Руководство для практикующих врачей-2 изд. исп., и доп./ под общ. ред. Н.А. Лопаткина, Т.С. Перепановой. М.:Литтерра, 2012.с. 303-318.
  4. Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Перепанова Т.С., Козлов Р.С. и исследовательская группа «ДАРМИС-2018» «Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исследования «ДАРМИС-2018». Клиническая микробиология и антимикробная химиотерапия. 2019;21(2):134-146. doi: 10.36488/cmac.2019.2.134-146.
  5. Sofia Ny, Petra Edquist, Uga Dumpis, Kirsi Gr'ondahl-Yli-Hannuksela, Julia Hermes, Anna-Maria Kling, Anja Klingeberg, Roman Kozlov, Owe K'allman, Danuta O.Lis, Monika Pomorska-Wesolowska, Mara Saule, Karin Tegmark Wisell, Jaana Vuopio, Ivan Palagin, Antibiotic resistance of Escherichia coli from outpatient urinary tract infection in women in six European countries including Russia (2018), https://doi.org/10.1016/j.jgar.2018.11.004
  6. Shang Y.J., Wang Q.Q., Zhang J.R., Xu Y.L., Zhang W.W., Chen Y., Gu M.L., Hu Z.D., Deng A.M. Systematic review and meta-analysis of flow cytometry in urinary tract infection screening. Clin Chim Acta 2013; 424: 90-95.
  7. Ana L. Flores-Mireles, Jennifer N. Walker, Michael Caparon, Scott J. Hultgren. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5): 269-284. doi: 10.1038/nrmicro3432
  8. Takashi Hato, Pierre C. Dagher. How the Innate Immune System Senses Trouble and Causes Trouble. Clin J Am Soc Nephrol. 2015;10(8):1459-1469. doi: 10.2215/CJN.04680514
  9. Gerard Apodaca. The Uroepithelium: Not Just a Passive Barrier. Traffic. 2004;5:117-128. doi: 10.1046/j.1600-0854.2003.00156.x
  10. Wagenlehner F.M. et al. Uncomplicated urinary tract infections. Dtsch Arztebl Int. 2011; 108:415. https://www.ncbi.nlm.nih.gov/pubmed/21776311
  11. Alidjanov J.F., Abdufattaev U.A., Makhsudov S.A., Pilatz A., Akilov F.A., Naber K.G., Wagenlehner F.M. New self-reporting questionnaire to assess urinary tract infections and differential diagnosis: acute cystitis symptom score. Urol Int. 2014;92:230-236. Urol Int 2016;96:369.
  12. Alidjanov J.F., Abdufattaev U.A., Makhsudov S.A., Pilatz A., Akilov F.A., Naber K.G., Wagenlehner F.M: The acute cystitis symptom score for patient-reported outcome assessment. Urol Int. 2016;97:402-409.
  13. Naber K.G., Алиджанов Ж.Ф. Существуют ли альтернативные методы антибактериальной терапии и профилактики неосложненных инфекций мочевыводящих путей? Урология. 2014;6:5-13.
  14. Chapple C.R. Is a voiding diary really necessary in 2014? Eur Urol. 2014;66(2):301-302. doi: 10.1016/j.eururo.2014.05.001.
  15. Bright E., Drake M.J., Abrams P. Urinary diaries: evidence for the development and validation of diary content, format, and duration. Neurourol Urodyn. 2011;30(3):348-352. doi: 10.1002/nau.20994.
  16. Bonkat G., Bartoletti R.R., Bruyere F., Cai T., Geerlings S.E., Koves B., Schubert S., Wagenlehner F. EAU Guidelines on Urological Infections European Association of Urology 2019. 52 p.
  17. Kaltenis P., Baciulis V., Liubsis A. Reliability of detection of leucocyturia by means of the dip-stick Cytur-Test.Int Urol Nephrol. 1984;16(3):233-235.
  18. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014; 28:1-13.
  19. Hooton T.M., Roberts P.L., Cox M.E., Stapleton A.E. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med. 2013;369(20):1883-1891. doi: 10.1056/NEJMoa1302186;
  20. Перепанова Т.С., Козлов Р.С., Руднов В.А., Синякова Л.А. «Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов» Федеральные клинические рекомендации 2017. 70 с.
  21. Colgan R., Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011;84(7):771-776.
  22. Guglietta A. Recurrent urinary tract infections in women: risk factors, etiology, pathogenesis and prophylaxis. Future Microbiol. 2017;12:239-246.
  23. McLellan L.K., Hunstad D.A. Urinary Tract Infection: Pathogenesis and Outlook. Trends Mol Med. 2016;22(11):946-957.
  24. Kaltenis P., Baciulis V., Liubsis A. Reliability of detection of leucocyturia by means of the dip-stick Cytur-Test.Int Urol Nephrol. 1984; 16(3):233-235.
  25. Lindsay E. Nicolle, Kalpana Gupta, Suzanne F. Bradley, Richard Colgan, Gregory P. DeMuri, Dimitri Drekonja, Linda O. Eckert, Suzanne E. Geerlings, Bela Köves, Thomas M. Hooton, Manisha Juthani-Mehta, Shandra L. Knight, Sanjay Saint, Anthony J. Schaeffer, Barbara Trautner, Bjorn Wullt, Reed Siemieniuk. IDSA 2019 Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria Clinical Infectious Diseases 2019: 3/21/2019. https://doi.org/10.1093/cid/ciy1121)
  26. Kranz J., Schmidt S., Lebert C., Schneidewind L., Mandraka F., Kunze M., Helbig S., Vahlensieck W., Naber K., Schmiemann G., Wagenlehner F.M. The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients: Part I. Urol Int 2018.
  27. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). EUCAST Definitive Document E.Def 1.2, May 2000: Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect. 2000;6(9):503-508.
  28. Wagenlehner F.M.E., Naber K.G. Asymptomatic bacteriuria - shift of paradigm. Clin Infect Dis. 2012;55:778-779.
  29. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon. 2003;49:53-70.
  30. Chu C.M., Lowder J.L. Diagnosis and treatment of urinary tract infections across age groups. Am J Obstet Gynecol. 2018;219(1) :40-51. doi: 10.1016/j.ajog.2017.12.231.
  31. Урология: национальное руководство/ под ред. Н.А. Лопаткина. М.: ГЭОТАР-Медиа, 2009 с. 484-490 (Серия «Национальные руководства») ISBN 978-5-9704-0983-1
  32. Puech P., Lagard D., Leroy C., Dracon M., Biserte J., Lemaitre L. Imaging in urinary tract infections in adults. J Radiol. 2004;85(2 Pt 2):220-240.
  33. Christiaens T.C., de Meyere M., Verschraegen G., Peersman W., Heytens S., de Maeseneer J.M. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract 2002;52:729-734.
  34. Falagas M.E., Kastoris A.C., Kapaskelis A.M., Karageorgopoulos D.E. Fosfomycin for the trea tment of multidrug-resistant, including extended-spectrum ß-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43-50. www.thelancet.com/infection Vol. 10 January 2010
  35. Tommaso Cai, Irene Tamanini, Carlo Tascini, Bela Köves, Gernot Bonkat, Mauro Gacci, Andrea Novelli, Juan Pablo Horcajada, Truls E. Bjerklund Johansen, George Zanel. Fosfomycin Trometamol versus Comparator Antibiotics for the Treatment of Acute Uncomplicated Urinary Tract Infections in Women: A Systematic Review and Meta-Analysis. J Urol. 2020;203(3):570-578. https://doi.org/10.1097/JU.0000000000000620
  36. Patel S.S., Balfour J.A., Bryson H.M. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53(4) :637-656. doi: 10.2165/00003495199753040-00007.
  37. Keating G.M. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs. 2013;73(17):1951- 1966. doi: 10.1007/s40265-013-0143-y.
  38. Лоран О.Б., Петров С.Б., Синякова Л.А., Перепанова Т.С., Винаров А.З., Косова И.В. Эффективность применения фосфомицина трометамола (Монурала 3г) в лечении больных хроническим рецидивирующим циститом. Эффективная фармакотерапия. Урология и нефрология. 2008;4:14-16).
  39. Dawson-Hahn E.E., Mickan S., Onakpoya I., Roberts N., Kronman M., Butler C.C., Thompson M.J. Short-course versus long-course oral antibiotic treatment for infections treated in outpatient settings: a review of systematic reviews. Fam Pract. 2017;34(5):511-519.
  40. Галкин В.В., Довгань Е.В., Козлов С.Н., Рафальский В.В. Цефиксим в сравнении с ципрофлоксацином при остром неосложненном цистите: клинико-экономическое исследование. Клиническая микробиология и антимикробная химиотерапия. 2012;14(1):59-66).
  41. Bader M.S., Loeb M., Brooks A.A. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2017;129(2):242-258. doi: 10.1080/00325481.2017.1246055.
  42. Jennifer Anger, Una Lee, A. Lenore Ackerman, Roger Chou et al. American Urological Association (AUA)/Canadian Urological Association (CUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) “Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline”/Copyright © 2019 American Urological Association Education and Research, Inc.®, 36 s.
  43. Elisabetta Costantini, Alessandro Zucchi, Eleonora Salvini, Annarita Cicalese, Vincenzo Li Marzi, Maria Teresa Filocamo, Vittorio Bini, Massimo Lazzeri. Prulifloxacin vs fosfomycin for prophylaxis in female patients with recurrent UTIs: a non-inferiority trial.Int Urogynecol J. 2014;25(9): 1173-1178. doi: 10.1007/s00192-013-2318-1.
  44. Raz R., Gennesin Y., Wasser J., Stoler Z., Rosenfeld S., Rottensterich E., et al. Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis. 2000;30:152e6.
  45. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999;5:1072e9.
  46. Perrotta C., Aznar M., Mejia R., Albert X., Ng C.W. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women (Review).Cochrane Database Syst Rev 2008;2:CD005131.
  47. Ivanov D., Abramov-Sommariva D., Moritz K., Eskötter H., Kostinenko T., Martynyuk L., Kolesnik N., Naber K.G. An open label, non-controlled, multicentre, interventional trial to investigate the safety and efficacy of Canephron® N in the management of uncomplicated urinary tract infections (uUTIs). Clinical Phytoscience. 2015;1:7. doi: 10.1186/s40816-015-0008-x. ;
  48. Gessner A. The influence of urologic therapeutics on the microbiome in an experimental model” in “How the microbiome is influenced by the therapy of urological diseases: standard vs. alternative approaches”. 31st Annual EAU Congress, Munich 2016.
  49. Naber K.G. Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Research and Reports in Urology, Dovepress, 2013:5 39-46.
  50. Dimitri Abramov-Sommariva, Martina Höller, Hubert Steindl,Kurt G. Naber. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, randomized, Multicentre, Non-Inferiority Phase III Trial Florian M. Wagenlehner.Internationalis Urologia. doi: 10.1159/000493368, Published online: September 19, 2018.
  51. Beerepoot M.A., Geerlings S.E., van Haarst E.P., van Charante N.M., ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol 2013;190:1981-1989.
  52. Kurt G. Naber, Yong-Hyun Cho, Tetsuro Matsumoto, Anthony J Schaeffer Immunoactive prophylaxis of recurrent urinary tract infections: a metaanalysis.International Journal of Antimicrobial Agents 2009;33:111-119. doi: 10.1016/j.ijantimicag.2008.08.011.
  53. Aziminia N., Hadjipavlou M., Philippou Y., Pandian S.S., Malde S., Hammadeh M.Y. Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int. 2019;123(5):753-768. doi: 10.1111/bju.14606. Epub 2018 Dec 19. PMID: 30378242.
  54. Albert X., et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev, 2004: CD001209, http:/www.ncbi.nlm.nih.gov/pubmed/15266443
  55. Osamwonyi B., Foley C. Management of recurrent urinary tract infections in adults, Surgery 2017. http://dx.doi.org/10.1016/j.mpsur.2017.03.004
  56. Costantini E., Lazzeri M., Pistolesi D., Del Zingaro M., Frumenzio E., Boni A., Pietropaolo A., Fragala E., Porena M. Morphological changes of bladder mucosa in patients who underwent instillation with combined sodium hyaluronic acid-chondroitin sulphate (Ialuril®).Urol Int. 2013;91(1):81- 88. doi: 10.1159/000345047.
  57. Madersbacher H., van Ophoven A., van Kerrebroeck P.E. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans--a review. Neurourol Urodyn. 2013;32(1):9-18. doi: 10.1002/nau.22256. Epub 2012 Jul 10.
  58. Rocco Damiano The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease Ther Adv Urol. 2011;3(5):223-232. doi: 10.1177/1756287211418723

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies